Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases
| Autor: | J Scheele, A Altendorf-Hoffmann, C Rudroff, R. Stangl |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Colorectal cancer Mitomycin medicine.medical_treatment Antineoplastic Combined Chemotherapy Protocols Hepatectomy Humans Infusions Intra-Arterial Medicine Survival rate Aged Neoplasm Staging Chemotherapy business.industry Liver Neoplasms Mitomycin C Middle Aged medicine.disease Combined Modality Therapy Surgery Survival Rate Chemotherapy Adjuvant Fluorouracil Cardiothoracic surgery Lymphatic Metastasis Female Colorectal Neoplasms business Follow-Up Studies medicine.drug Abdominal surgery |
| Zdroj: | Langenbeck's Archives of Surgery. 384:243-249 |
| ISSN: | 1435-2451 1435-2443 |
| Popis: | Background and aims: The liver represents the predominant site of cancer relapse after curative resection of hepatic metastases from colorectal carcinoma. Adjuvant intra-arterial chemotherapy was therefore considered a promising therapeutic approach in high-risk patients. Patients/methods: From July 1984 to December 1985, a total of 42 consecutive patients underwent R0 resection of colorectal liver metastases. Thirty patients with mesenteric lymph-node metastases (Dukes C) were randomised into two groups. In 14 group-A patients, a hepatic artery port catheter was placed during liver resection. Four courses of adjuvant chemotherapy were administered at 4-week intervals, consisting of mitomycin C (8 mg/m2, day 1) and 5-fluorouracil (800 mg/m2, days 1–5). Sixteen group-B patients served as controls. The 12 patients with no mesenteric lymph-node metastases (Dukes A/B) were included in the follow-up program. Results: After 5 years, 64% of Dukes A/B patients and 29% of Dukes C patients were alive (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink